The company is sounding confident on getting the funding to get the P results and analyze them. "Additional funding" would be just that, and subsequently used for the next thing in the priority line, the K pill.
This is good to see and I hope they are in fact having no problems getting funding for the P results. They shouldn't be, there's a lot of PE capital out there looking for good risk/return.